香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示概不對因本公告全部或 任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 華潤醫療控股有限公司 董事長 于海 中國，2025年8月14日 於本公告日期，董事會成員包括執行董事于海先生、單寶杰先生及楊敏女士；非 執行董事葛路女士；獨立非執行董事胡定旭先生、傅廷美先生、周鵬先生及羅詠 詩女士。 （於開曼群島註冊成立的有限責任公司） （股份代號：1515） 董事會會議日期 華潤醫療控股有限公司（「本公司」）董事（「董事」）會（「董事會」）茲通告謹定於2025 年 8 月 26 日（ 星 期 二 ）舉 行 董 事 會 會 議 ， 以 考 慮 及 通 過 本 公 司 及 其 附 屬 公 司 截 至 2025 年6 月 30 日 止六個 月的綜 合中期 業績及 其發佈 、考慮 派發中 期股 息（ 如有 ）， 以及處理其他事項。 承董事會命 ...

智通财经APP获悉，根据联交所资料显示，8月5日，富达国际增持华润医疗(01515)291.15万股，每股作 价3.6936港元，总金额约为1075.39万港元。增持后最新持股数目约为1.05亿股，最新持股比例为8.1%。 本交易涉及其他关联方：Pandanus Associates Inc.、Pandanus Partners L.P.。 ...

根据2025年8月6日披露数据，华润医疗（01515）、长飞光纤光缆（06869）、英诺赛科（02577）港股 通持股占比增加值最大，分别增加3.12%、1.71%、1.12%；恆生中国企业（02828）、盈富基金 （02800）、龙蟠科技（02465）港股通持股占比减少值最大，分别减少-18.37%、-8.53%、-3.07%。 2、港股通最新日占比减持榜（前20名） | 公司名称 | 占比值变动 | 最新持股比例 | | --- | --- | --- | | 恆生中国企业(02828) | -18.37% | 0.65% | | 盈富基金(02800) | -8.53% | 0.65% | | 龙蟠科技(02465) | -3.07% | 48.38% | | 南方恆生科技(03033) | -2.60% | 59.94% | | 山东墨龙(00568) | -2.14% | 56.01% | | 重庆钢铁股份(01053) | -2.05% | 33.91% | | 优必选(09880) | -1.08% | 25.40% | | --- | --- | --- | | 宜搜科技(02550) | - ...

Core Viewpoint - The healthcare sector in Hong Kong is experiencing significant turbulence, primarily due to the impact of medical insurance cost control policies and the transition to a new payment system, which is leading to declining profits for companies like China Resources Medical [1][3][11]. Company Summary - China Resources Medical's stock price plummeted by 15.58% on August 4, reaching a closing price of HKD 3.73, with a market capitalization of HKD 48.5 billion [1]. - The company issued a profit warning, expecting a 20%-25% year-on-year decline in profits for the first half of the year, with a projected 55%-60% drop in net profit attributable to shareholders after excluding one-time gains of HKD 210 million [1][3]. - In 2024, the company reported a revenue of HKD 9.855 billion, a decrease of 2.5% year-on-year, primarily due to the impact of medical insurance cost control, with outpatient and inpatient average revenue per case declining by 2.4% and 4.3%, respectively [3][11]. - The company is gradually exiting the Investment-Operation-Transfer (IOT) business model, which has also contributed to the decline in profits, indicating a structural adjustment in its business operations [4][5]. Industry Summary - The challenges faced by China Resources Medical are reflective of broader issues within the healthcare industry, as many private hospitals are experiencing pressure on their performance due to similar factors [6][12]. - International Medical, another major player, has forecasted a net loss of HKD 160 million to HKD 170 million for the first half of 2025, attributing this to market fluctuations and the impact of the DRG payment reform [6][7]. - The DRG payment reform, set to deepen in 2025, fundamentally alters the revenue model for hospitals, shifting from fee-for-service to fixed payments based on disease categories, which limits revenue growth opportunities [3][11]. - The industry is witnessing a trend of increasing differentiation, with companies like International Medical focusing on high-value medical services and diversifying into non-insurance revenue streams to mitigate the impact of declining average fees [8][12]. - The ongoing reforms are expected to force hospitals to enhance cost control and management efficiency, leading to a healthier industry structure in the long term, despite short-term performance pressures [11][12].

本文源自：金融界 预期利润下降主要由于医保次均用下降致成员医疗机构经管利润下降。同时本公司逐渐退出IOT(即投 资-运营-移交模式)业务，其对应的利润贡献下降。2025年下半年本公司将继续积改善收入结构，推动管 理精细化，控制运管成本，提高经营效益。 | 香港交易及结算所有限公司及香港哪合交易所有限公司對本公告的内容廣不良 | 本公司仍在落實本則國於報告開之起合財務嚴表。本公告所載資料乃慰獲本公司 | | --- | --- | | 青、封其律破性设完整性冰不管表任何登明,崇明建表示题不到国本公告全高或 | Ⅰ 面已有资料 · 以及男本集膳波腹含刷风未提酱肝的综合管理服目之初步評估面 | | 任何部分歧容画產生或因綺麗華內容面引發的任何損失承擔任何责任。 | 作出 · 商〔等資料商未服本公司溶胚委員會及本公司之程數間簽回 · | | | 服東及滑在投資者於買賣本公司股份時期購獲得利率從建議參考本公司於2025年 | | > 華潤醫療控股有限公司 | 8月底開啟報告開樂刊發的中開風蘭公告所載之詳情, | | China Resources Medical Holdings Company Limited | 产 ...

大摩指出，公司将利润下降归因于平均医疗保险每次就诊费用减少，显示各地区受DRG/DIP2.0导致的 报销压力加剧。大摩认为这对其他依赖公共保险的医院营运商，如海吉亚医疗(06078)、锦欣生殖 (01951)和爱尔眼科（300015）(300015.SZ)构成负面影响。 摩根士丹利发布研报称，华润医疗(01515)发布今年上半年利润警告，普通股股东应占净利润预计同比 下降20%至25%。若剔除与"燕化IOT协议"相关的2.1亿元人民币补偿，基础业务利润将同比下降55%至 60%，低于市场共识和大摩的预估。大摩予华润医疗目标价3港元，评级"减持"。 ...

Group 1 - Morgan Stanley reports that China Resources Medical (01515) has issued a profit warning for the first half of the year, with net profit attributable to ordinary shareholders expected to decline by 20% to 25% year-on-year [1] - Excluding the 210 million RMB compensation related to the "Yanhua IOT Agreement," the underlying business profit is projected to decrease by 55% to 60%, falling below market consensus and Morgan Stanley's estimates [1] - The company attributes the profit decline to a reduction in average medical insurance reimbursement per visit, indicating increased reimbursement pressure across regions due to DRG/DIP 2.0 [1] Group 2 - Morgan Stanley sets a target price of 3 HKD for China Resources Medical and maintains a "Reduce" rating [1] - The report suggests that the profit decline could negatively impact other hospital operators reliant on public insurance, such as Haijia Medical (06078), Jinxin Fertility (01951), and Aier Eye Hospital (300015.SZ) [1]

Core Viewpoint - Morgan Stanley's research report indicates that China Resources Medical has issued a profit warning for the first half of this year, with net profit attributable to ordinary shareholders expected to decline by 20% to 25% year-on-year [1] Financial Performance - Excluding a compensation of 210 million yuan related to the YanHua IOT agreement, the underlying business profit is projected to decline by 55% to 60% year-on-year, which is below market consensus and Morgan Stanley's estimates [1] - Morgan Stanley sets a target price of 3 HKD for China Resources Medical and maintains a "Reduce" rating [1] Industry Impact - The company attributes the profit decline to a reduction in average medical insurance reimbursement per visit, indicating increased reimbursement pressure across regions due to DRG/DIP 2.0 [1] - This situation is expected to negatively impact other hospital operators that rely on public insurance, such as Haijia Medical, Gushengtang, Jinxin Fertility, and Aier Eye Hospital [1]

Group 1: Pharmaceutical Regulations - Starting from August 1, all retail pharmacies in Foshan will implement a real-name registration system for the sale of 47 key controlled drugs, primarily for treating symptoms of Chikungunya fever [1] - The list of controlled drugs includes common medications such as Ibuprofen, Compound Cold Medicine, and Lianhua Qingwen capsules [1] Group 2: Clinical Trials and Drug Approvals - Kangning Jereh's innovative drug JSKN022, a PD-L1/αvβ6 dual-specific antibody drug conjugate, has received acceptance for clinical trial application from the National Medical Products Administration [3] - Yipin Hong's innovative drug APH03621 for endometriosis treatment has also received clinical trial registration acceptance from the National Medical Products Administration [5] - Lianhua Pharmaceutical's subsidiary has passed the consistency evaluation for the generic drug Lincomycin Hydrochloride Injection [4] Group 3: Financial Performance - China Resources Medical expects a profit decline of 20% to 25% for the first half of the year, with a significant drop of 55% to 60% when excluding one-time gains [6] - Zhenghai Bio reported a net profit of 46.49 million yuan for the first half of 2025, a decrease of 45.97% year-on-year, with revenue of 188 million yuan, down 5.14% [8] Group 4: Corporate Actions - Kexing Bio has spent 47.38 million yuan to repurchase 1.27 million shares, representing 0.63% of its total share capital [8] - WuXi AppTec has repurchased 6.51 million A-shares for a total of 497 million yuan [10] - Tian Tan Bio has decided to abandon the acquisition opportunity of Pailin Bio due to potential competition with its core business [9] Group 5: Industry Developments - Significant progress has been made in HIV vaccine research in China, with the completion of the first phase clinical trial for a replicating Tian Tan smallpox vaccine carrier HIV vaccine [11][13] - Sanofi announced the discontinuation of its PCSK9 inhibitor drug Alirocumab in China due to global supply issues and a strategic shift in its cardiovascular product line [12]

Group 1 - Sanofi has confirmed the cessation of its cholesterol-lowering drug "Polaida" (generic name: Alirocumab injection) supply in the Chinese market due to global supply issues and strategic optimization in the cardiovascular market [1] - This decision may lead investors to reassess Sanofi's positioning in the competitive Chinese cholesterol drug market, potentially impacting its market share and revenue expectations, which could affect stock performance and investor confidence [1] Group 2 - China Resources Medical has issued a profit warning, expecting a year-on-year profit decline of approximately 20% to 25% for the first half of the year, primarily due to a decrease in average medical insurance expenses affecting the profitability of member medical institutions [2] - Excluding one-time gains, the profit decline is more pronounced, indicating pressure on the company's core business, which may impact investor confidence and put short-term pressure on stock prices [2] Group 3 - AI pharmaceutical company Jitai Technology has announced the completion of a 400 million RMB Series D financing round, led by Beijing Medical Health Industry Investment Fund and Daxing District Industrial Investment Fund [3] - The funding will accelerate the advancement of Jitai Technology's strategic priorities, indicating recognition of the company's technology and market potential, which may enhance competitiveness and attract more attention [3] Group 4 - Tiantan Biological has announced its intention to abandon the acquisition opportunity of Pailin Biological, aligning with its prudent management approach to protect investor interests [4] - This decision is not expected to adversely affect the company's operations, and investors are encouraged to monitor further commitments from China Biological regarding the acquisition [4] Group 5 - The National Healthcare Security Administration has held five symposiums to discuss support for innovative drugs and medical devices, outlining five key directions for policy support [5] - These discussions are expected to enhance market confidence in innovative pharmaceutical companies, attract more investment into drug development, and boost valuations in the sector, contributing to the long-term growth of the innovative drug market [5]